Role of matrix metalloproteinases in joint destruction in rheumatoid arthritis

1. <div><p>Birkedalhansen Н. Role of matrix metalloproteinases in human periodontal diseases. J. Periodontol., 1993, 64, 474484</p><p>Birkedal-Hansen H. Proteolytic remodeling of extracellular matrix. COCB, 1995, 7. 728-735</p><p>Ichikawa Y., Yamada C., Horiki T. et al. Serum matrix metalloproteinase-3 and fibrin degradation product levels correlate with clinical disease activity in rheumatoid arthritis. Clin. Exper. Rheuniat., 1998, 16, 533-540</p><p>Jackson C., Nguyen М., Arkell J., Sambrook P. Selective matrix metalloproteinase (MMP) inhibition in rheumatoid arthritis - Targeting gelatinase A activation. Inflam. Res., 2001, 50, 183-186</p><p>Dreier R. Wallace S., Fuchs S. et al. Paracrine interactions of chondrocytes and macrophages in cartilage degradation: articular chondrocytes provide factors that activate macrophage-derived pro-gelatinase В (pro-MMP-9). J. Cell Scient., 2001, 114, 3813-3822</p><p>Obata K., lwata K., Okada Y. el al. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 3 (stromelysin-1) using monoclonal antibodies. Clin. Chim, Acta, 1992, 15.211,59-72</p><p>Cawston T.E. Metalloproteinase inhibitors and the prevention of connective tissue breakdown. Pharmacol. Therap., 1996, 70, 163-182</p><p>Arend W.P, Dayer J.P. Cytokines and cytokine inhibitors in rheumatoid arthritis. Arthr. Rheum., 1990, 33, 305-315</p><p>Brennan F.M., Browne K.A., Green P.A. et al. Reduction of serum matrix metalloproteinase 1 and matrix metallo- proteinase 3 in rheumatoid arthritis patients following antitumor necrosis factor therapy. Br. J.t Rheum., 1997, 36, 643-650</p><p>Nagase H., Woessner J.F. Matrix metalloproteinases. J. Biol. Chem., 1999, 274. 21491-21494</p><p>Clark I.М., Rowan A.D., Cawston T.E. Matrix metalloproteinase inhibitors in the treatment of arthritis. Curr. Opin. Anti-lnflamm. Immun. Invest. Drugs, 2000, 2, 1625.</p><p>Vu Т.Н., Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes. Dev., 2000, 14, 2123-2133</p><p>Maeda S., Sawai Т., Uzuki M. et al. Determination оГ interstitial collagenase (MMP-1) in patients with rheumatoid arthritis. Ann. Rheum. Dis. ,1995, 54, 970-975</p><p>Wooley D.E., Crossley M.J., Evanson J.M. Collagenase at sites of cartilage erosion in the rheumatoid joint. Arthr. Rheum., 1977, 20, 5625-5628</p><p>Cunnane G., Fitzgerald O., Beeton C. et al. Early joint erosions and serum levels of matrfx metalloproteinase I, matrix metalloproteinase 3, and tissue inhibitor of metalloproteinases I in rheumatoid arthritis. Arthr. Rheum., 2001, 44, 2263-2274</p><p>Grinnell F., Zhu М., Parks W.C. Collagenase-1 complexes with alpha2-macroglobulin in the acute and chronic wound environments. J. Invest. Dermatol., 1998, 110, 771776 •</p><p>Murphy G., Knauper V., Atkinson S. et al. Matrix metalloproteinases in arthritic disease. Arthr. Res., 2002, 4, suppl. 3, 39-49</p><p>Goldbach-Mansky R., Lee J.M., Hoxworth J.M. et al. Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis. Arthr. Res., 2000, 2, 145-53</p><p>Sasaki S., Iwata H., Ishiguro N. et al, Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis. Clin. Rheumatol,, 1994, 13(2), 228-333</p><p>Yoshihara Y., Obata K., Fujimoto N. et al. Increased levels of stromelysin-1 and tissue inhibitor of metallopro- teinases-1 in sera from patients with rheumatoid arthritis. Arthr. Rheum., 1995, 38(7), 969-975</p><p>Ishiguro N. Ito Т., Obata K. et al. Determination of stromelysin-1, 72 and 92 kDa type IV collagenase, tissue inhibitor of metalloproteinase-1 (TIMP-I), and TIMP-2 in synovial fluid and serum from patients with rheumatoid arthritis. J. Rheumatol., 1996, 23(9), 1599-1604</p><p>Okada Y., Takeuchi N. Tomita K. et al.lmmunolocalization of matrix metalloproteinase 3 (stromelysin) in rheumatoid synovioblasts (B cells): correlation with rheumatoid arthritis. Ann. Rheum. Dis., 1989, 48, 645-653</p><p>Ronday H.K., Smits H.H., Van Muijen G.N. et al. Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Br. J. Rheumatol., 1996, 35(5), 416-423</p><p>Tchetverikov 1., Lard L.R., DeGroot J. et al. Matrix met- alloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann. Rheum. Dis., 2003, 62(11), 1094-1099</p><p>Krane S.М., Amento E.P., Goldring M.B. et al. Research monographs in cell and tissue physiology. Amsterdam, Elsevier, 1988, 15, 179-195</p><p>Brinckerhoff C.E. Joint destruction in arthritis: metalloproteinase in the spotlight. Arthr. Rheum.-, 1991, 34, 10731075</p><p>Werb Z., Alexander C. Proteinases and matrix degradation. In: Kelley WN Harris ED Ruddy S Sledge CB, eds. Textbook of rheumatology. 4th ed. Vol. 14. Piladelphia: Saunders, 1993, 248-268 '</p><p>Stevens R. Presentation; ACR 2000: State of the art review of matrix metalloproteinase inhibitors (oral presentation).</p><p>Martel-Pelletier J., Fujimoto N. Obata K. Cloutier et al. The imbalance between the synthesis level of metalloproteinases and TIMPs in osteoarthritic and rheumatoid arthritis cartilage can be enhanced by interleukin-l [abstract|. Arthr. Rheum., 1993, 36, 191</p><p>Martel-Pelletier J., McCollum R., Fujimoto N. et al. Excess of metalloproteases over tissue inhibitor of metaljo- protease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab. Invest., 1994, 70, 807-815</p><p>Close D.R. Matrix metalloproteinase inhibitors in rheumatic diseases. Ann. Rheum. Dis.,2001, 60 (suppl 3), II162-11167</p><p>Walsh D.A. Angiogenesis and arthritis. Rheumatology (Oxford),1999, 3S. 103-112</p><p>Murphy G., Crabbe T. Gelatinase A and B. Methods in Enzymol., 1995, 248, 470-484</p><p>Posthumus M.D., Limburg P.C., Westra J. et al. Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological progression. J. Rheumatol., 2000, 12, 27, 2761-2768</p><p>Keyszer G., Lambiri 1., Nagel R. et al. Circulating levels of matrix metalloproteinases MMP-3 and MMP-I, tissue inhibitor of metalloproteinases I (TIMP-I), and MMP- 1/TIMP-l complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers. J. Rheumatol., 1999, 26(2), 251-258</p><p>Yamanaka H., Matsuda Y., Tanaka M. et al. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthr. Rheum., 2000, 43, 852-855</p><p>Posthumus M.D., Limburg P.C., Westra J. et a). Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis. Rheumatology (Oxford), 1999, 38, 1081-1087</p><p>So A., Chamot A.M., Peclat V., Gerster J.C. Serum MMP-3 in rheumatoid arthritis: correlation with systemic inflammation but not with erosive status. Rheumatol., 38, 407-410</p><p>Ishiguro N. ho Т., Miyazaki K., Iwata H. Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and glycosaminoglycans in synovial fluid from patients with rheumatoid arthritis. J. Rheumatol., 1999, 26(1), 34-40</p><p>Roux-Lombard P., Eberhardt K., Saxne T. et al. Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study. J. Rheumatol., 2001, 40, 544-551</p></div><br />